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Abstract
Background: Chromosomal deletions encompassing DYRK1A have been associated with intellectual disability for
several years. More recently, point mutations in DYRK1A have been shown to be responsible for a recognizable
syndrome characterized by microcephaly, developmental delay and intellectual disability (ID) as well as
characteristic facial features. Here we present 2 individuals with novel mutations in DYRK1A, and a review of the
cases reported to date.
Case presentation: Both individuals presented with the well-known characteristic features, as well as rarer
anomalies seen in a minority of patients. Patient 1 presented shortly after birth with an enlarged cisterna magna,
distal contractures, and distinctive facies that included bitemporal narrowing and deep set eyes. A de novo splice
site mutation in DYRK1A [c.951 + 4_951 + 7delAGTA; p.Val222Aspfs*22] was identified by next generation
sequencing. Patient 2 presented at 7 months of age with microcephaly and dysmorphic features. She went several
years without a diagnosis until a de novo DYRK1A nonsense mutation [c.787C>T; p.(Arg263*)] was identified at age
12. These individuals, and the 52 cases reviewed from the literature, show the characteristic features of the DYRK1A-
related syndrome including global developmental delay, ID, microcephaly, feeding difficulties, and the facial gestalt.
Other common findings include seizures, vision defects, brain abnormalities and skeletal abnormalities of the hands
and feet. Less common features include optic nerve defects, contractures, ataxia, and cardiac anomalies.
Conclusion: DYRK1A testing should be considered in individuals with the facial features, intellectual disability and
post-natal microcephaly. Once diagnosed with DYRK1A-related intellectual disability, a cardiac and ophthalmologic
assessment would be recommended as would routine surveillance by a pediatrician for psychomotor development,
growth, and feeding.
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Background
The dual-specificity tyrosine phosphorylation-regulated
kinase 1A (DYRK1A) (MIM 600855) is located in the
Down syndrome critical region of chromosome 21 [1]. It
encodes a highly conserved protein that plays an essen-
tial role in the development of the central nervous sys-
tem [2–4]. Haploinsufficiency of DYRK1A is responsible
for a syndrome characterized by intellectual disability
(ID), microcephaly and dysmorphic features (MIM
614104). Individuals with this condition were initially re-
ported with partial monosomies of chromosome 21 as
detected on routine karyotype that encompassed the
DYRK1A gene (21q22.13) [5–7]. Since then, numerous
cases of chromosome 21 deletions diagnosed by com-
parative genomic hybridization have been reported by
several groups [8–13]. The first intragenic frameshift de-
letion, identified by direct sequencing, was described by
Courcet et al in 2012 [14]. More recently, next gener-
ation sequencing (NGS) has led to the diagnosis of
numerous de novo mutations in DYRK1A, further char-
acterizing, and broadening, this syndromic phenotype
[15–21]. To date, there have been 52 individuals in the
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literature with the DYRK1A-related ID phenotype with
both structural rearrangements (n = 19) and more re-
cently, single nucleotide variants and small insertions/
deletions within DYRK1A (n = 33).
Here, we present 2 additional patients with novel
DYRK1A mutations. We also provide a comprehensive
review of the previously published cases, further delin-
eating both the common and less commonly seen fea-
tures of this emerging syndrome.
Case presentations
Patient 1 was born at 36 + 3 weeks, to healthy parents of
Iraqi origin. Parents were first cousins once removed.
Two older siblings were in good health. There was no
family history of ID or congenital anomalies. Intrauter-
ine growth restriction (IUGR) and an enlarged cisterna
magna were observed at 35 weeks by routine ultrasound.
A prenatal diagnosis of Dandy-Walker malformation
was considered but ruled out with post-natal MR
imaging (Fig. 1c). Labor was induced given poor fetal
growth and the patient was born by vaginal delivery at
36 + 3 weeks. At birth, APGAR scores were 6 and 8 at 1
and 5 min. Birthweight was 2.33 kg (−2.5 SD) and head
circumference was 31.5 cm (−2.5 SD). On examination
he had a sacral dimple, increased appendicular tone, and
bilateral contractures to the third and fifth digits
(Fig. 1d). An echocardiogram showed a patent ductus
arteriosus. He experienced feeding difficulties in the
neonatal period and required nasogastric feeding.
MRI at 2 weeks of life showed mild prominence of lat-
eral ventricles and extra-axial spaces, enlarged cisterna
magna, and a thin corpus callosum. MRI repeated at
10 months of age showed interval enlargement of the
supratentorial extra-axial spaces, mild dilatation of the
lateral and 3rd ventricles as well as the enlarged cisterna
magna and thin corpus callosum (Fig. 1c).
The patient’s facial features showed bitemporal nar-
rowing with down-slanted palpebral fissures, deep-set
eyes with hooded appearance, a prominent nasal root,
low-set and mildly dysplastic ears, and a downturned
mouth (Fig. 1a, b). He had bilateral ankle contractures
and proximal placement of the first toes. At 4 months of
age he continued to have contractures of ankles and 3rd
digits of his hands. He is currently followed for visual
impairment with bilateral optic atrophy. He has bilateral
hydronephrosis. He further has a history of recurring
otitis media with resultant conductive hearing loss. From
a young age, he has experienced frequent dysphagia and
emesis with ingestion of thicker liquids. At 15 months,
his weight was 7.9 kg (−3.3 SD) and length was 72.9 cm
(−2.2 SD). Head circumference showed relatively slower
growth velocity at 41.5 cm (−4.6 SD). At 21 months of
age, he had yet to stand or say his first words. A karyo-
type and microarray were normal. Given the history of
consanguinity and the syndromic features in Patient
1, the parents of the patient had genetic counselling
and were quoted a recurrence risk of up to 25 %.
The patient was enrolled in a research study at the
Children’s Hospital of Eastern Ontario, at the age of
13 months.
Patient 2 was born at 41 + 3 weeks by spontaneous vagi-
nal delivery, to healthy French Canadian parents. Parents
were not consanguineous. The patient has two older
siblings in good health. Birthweight was 3.2 kg (- 1.1 SD).
There were no concerns in the newborn period with
the exception of feeding difficulties. At 7 months of
age, she was referred to Genetics for microcephaly
and dysmorphic features. At that time she weighed
6.65 Kg (−1.5 SD), with length of 65.2 cm (- 1 SD).
Head circumference was 39.8 (−2.9 SD). On examin-
ation, she had bitemporal narrowing, a prominent





Fig. 1 The characteristic facies of 2 individuals with DYRK1A
mutation. a-b Patient 1 with bitemporal narrowing, down-slanted
palpebral fissures, deep-set eyes and dysplastic ears. c MR Images in
Patient 1 showing thin corpus callosum, enlarged cisterna magna
and 4th ventricle. d distal contractures seen in Patient 1. e-g Patient
2 with with bitemporal narrowing, deep-set eyes and dysplastic ears
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occiput and deep set eyes. In addition, she had a pro-
nounced asymmetry of the ears, with her right ear
being lower set, anteverted, and with a simple helix
(Fig. 1e-g). She underwent bilateral otoplasty at the
age of four.
She experienced several febrile seizures starting at
15 months of age. Her seizures continued in the absence
of fever, and she experienced a number of generalized
tonic-clonic seizures before beginning anticonvulsant
medication at 8 years of age. Her seizures have since
been well controlled, with low dose treatment with Leve-
tiracetam. An MRI, at 34 months of age, showed ventri-
cles and subarachnoid space in the upper limits of the
normal range but with no other structural abnormality.
She said her first word at 32 months. By 8 years of age
she had 10 words, and by 11 years, she occasionally
spoke in short sentences. She walked at 25 months. At
the age of 12, she was described as having a broad-based
clumsy gait, and exhibited a mild tremor and ataxia
when reaching for objects. As a toddler, she demon-
strated stereotypic behavior including hand flapping,
tongue thrusting during feedings, as well as an aversion
to being touched and to certain textures. Hand flapping
has persisted into adolescence. At 11 years of age, she
had a height of 159 cm (+2 SD), a weight of 56 Kg (+1.7
SD), and a head circumference of 51 cm (−1.3 SD). Dur-
ing her last assessment at age 12, her features were fur-
ther described as a long face, bitemporal narrowing,
hooded palpebral fissures, deep set eyes, prominent
nasal bridge and bulbous tip to her nose, smooth phil-
trum, wide spaced teeth, tapering fingers and mild pec-
tus excavatum (Fig. 1g).
During her diagnostic work-up she underwent several
investigations that included normal karyotype, chromo-
somal microarray, FISH for 22q11.2, methylation specific
MLPA and sequencing of UBE3A, sequencing of MECP1
and MECP2, TCF4, and mitochondrial DNA whole
genome sequencing all yielded normal results.
A
B C
Fig. 2 a Schematic representation of the coding sequence of DYRK1A (NM_001396.3) showing the localization of the two de novo mutations
identified in this study. b Agarose gel electrophoresis of the RT-PCR products from patient 1 (Pat 1) and a control individual (CTR). A fragment
covering exons 5–8 was amplified by RT-PCR (yellow in a). The expected 528 bp PCR product was observed from both patient 1 and the control
individual, whereas a smaller PCR product (~240 bp) was only detected in patient 1. A 100 bp ladder was used for reference. c Sequencing of
both the wild type (WT) and mutant fragments from patient 1 showing the WT DYRK1A transcript sequence covering exons 6 and 7, and mutant
DYRK1A transcript lacking exon 6, resulting in a frameshift and a premature stop codon 22 codons downstream
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Material and methods
Genomic DNA was extracted from peripheral blood
lymphocytes using standard methods. The Trusight
One Sequencing panel (Illumina) was used to capture
4813 genes deemed to be “clinically relevant”.
Enriched libraries from patient 1 and his parents (trio
approach) were pooled and sequenced on the MiSeq
(Illumina). The detailed protocol has been previously
reported [22]. RT-PCR and Sanger sequencing were
performed by standard protocols using primers target-
ing DYRK1A (NM_001396.3) coding exon-5 (Ex5F:5′-
TTGAGCTCATGAACAAACATGAC-3′) and coding
exon-8 (Ex8R:5′-GAGCAGGTGGAATACCCAGA-3′)
on RNA extracted from patient and control lympho-
blast cell lines.
Results and discussion
A de novo variant in DYRK1A [c.951 + 4_951 +
7delAGTA; p.Val222Aspfs*22] was identified in patient 1
at 14.5 months of age. This variant is predicted to affect
splicing by Alamut Visual version 2.7 (Interactive Bio-
software, Rouen, France) and was confirmed by RT-PCR
(Fig. 2b) and Sanger sequencing (Fig. 2c). Patient 2 had
clinical testing with a next-generation sequencing panel
for epilepsy (Comprehensive Epilepsy Panel; Medical
Neurogenetics Lab, Georgia, USA) and this revealed a
nonsense mutation [c.787C>T; p.(Arg263*)] in DYRK1A.
Parents were tested and found to not carry the mutation
in keeping with a de novo mutation.
Both individuals had novel DYRK1A mutations, and
presented with the key features of the DYRK1A pheno-
type, as well as less commonly observed findings that
contribute to a broadening of the phenotypic spectrum
of this recognizable syndrome. Patient 1 was seen pre-
natally given the IUGR and an enlarged cisterna magna
observed on routine prenatal ultrasound. At birth, camp-
todactyly, hypertonia, and distinctive facial features were
noted. A diagnosis occurred at 14.5 months of age and
was possible because of the early recognition of a likely
monogenic syndrome and accessibility to comprehen-
sive, NGS-based panel testing. In contrast, Patient 2 was
referred to Genetics given the history of a mild post-
natal microcephaly, dysmorphic features and develop-
mental delays. During her childhood she experienced an
extensive diagnostic odyssey with many genetic, meta-
bolic, and imaging investigations performed. A molecu-
lar diagnosis was also possible with NGS panel testing
for epilepsy-related genes at age 12 years.
A PubMed search for reported cases of DYRK1A mu-
tations or partial chromosome 21 deletions yielded a
total of 52 patients from 17 papers (Table 1). A summary
of the clinical features of the 2 patients and the previ-
ously published cases is shown in Table 2. We recognize
that any conclusions based on published data may enrich
for more severe phenotypes; however the relatively large
number of cases (n = 54) may attenuate this potential
source of bias. The age at diagnosis of the patients and
those from the literature showed a wide range from
17 months to 59 years. The 14.5 months observed for
patient 1 was the earliest reported molecular diagnosis.
On history, disease manifestations were early in most
patients and prenatal findings were observed in 33/43
(77 %). This included 21 cases of IUGR, 2 cases of oligo-
hydramnios and 1 case of polyhydramnios. Birth mea-
surements were commonly in the low range (<-2 SD),
though this was not universal. In aggregate, the most
common features were ID and developmental delay seen
in 53/53 cases (100 %), dysmorphic facies in 53/54
(98 %), feeding difficulties in 44/46 (96 %), and micro-
cephaly (<-2 SD) seen in 44/51 (86 %). A number of
other features were also noted in the majority such as
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Table 2 Summary of the clinical presentation of patients with DYRK1A mutations






Age at last reported
assessment





IUGR / prenatal findings IUGR, enlarged
cisterna magna
- 17 / 26 15 / 16 33 / 43
Head circumference
at birth (<-2 SD)
- 2.5 SD 13 / 22 15 / 16 29 / 39
Low birth weight (<-2 SD) - 2.5 SD - 13 / 27 14 / 19 28 / 47
Length at birth (<-2 SD) - - 12 / 21 12 / 15 24 / 36
Feeding difficulties + + 28 / 30 14 / 14 44 / 46
Microcephaly (<-2 SD) - 4.6 SD - 1.3 SD 26 / 31 17 / 18 44 / 51
Weight (<-2 SD) - 3.3 SD +1.7 SD 7 / 26 12 / 17 20 / 45
Height (<-2 SD) - 2.2 SD +2 SD 7 / 28 12 / 18 20 / 48
Global developmental delay + + 33 / 33 18 / 18 53 / 53
Intellectual disability + 31 / 32 19 / 19 51 / 52
Speech delay / absence + + 32 / 32 17 / 17 51 / 51
Motor delay / late walking + + 22 / 22 11 / 12 35 / 36
Abnormal gait + 18 / 20 7 / 9 26 / 30
Behavioral issues - + 29 / 31 9 / 11 39 / 44
Stereotypies - + 20 / 25 6 / 9 27 / 36
Autism spectrum disorder - 14 / 27 2 / 7 16 / 35
Anxiety - + 9 / 18 1 / 5 11 / 24
Hyperactivity / ADHD - - 5 / 21 3 / 7 8 / 30
Febrile seizures - + 17 / 29 13 / 15 31 / 46
Seizures / epilepsy - + 14 / 28 13 / 17 28 / 47
Brain abnormalities (MRI) + Normal 18 / 24 13 / 16 32 / 42
Enlarged ventricles + 10 4 22a
General / cortical atrophy + 8 6 17a
Thin brainstem - 2 2 13a
Hypoplastic corpus
callosum
- 2 4 9a
Optic disk/nerve
anomaly
Optic disc pallor - 5 1 7
Vision abnormalities Visual impairment - 16 / 21 8 / 9 25 / 32
Dysmorphic facies + + 32 / 33 19 / 19 53 / 54
Abnormalities of the
hands or feet
Small feet, toe brachydactyly,
proximal placement of first toes
Tapering fingers, high arched
feet
15 / 16 8 / 10 25 / 28
Abnormalities of the
spine or chest
- Mild pectus excavatum 6 / 8 4 / 7 11 / 17
Contractures Bilateral: third and fifth digits,
ankles
- 3 / - 1 / - 5 / -
Gastrointestinal
symptoms
GERD, vomiting - 13 / - 3 / - 17 / -
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stereotypies and abnormal gait (Table 2). Weight and
height at last clinical assessment were less than − 2 SD
in only 44 and 42 % respectively. There were 5 patients
who were within the normal range for height, weight
and head circumference.
Febrile seizures were reported in 31/46 (67 %) cases
and a later diagnosis of epilepsy or non-febrile seizures
was observed in 60 %. Patient 2 and 8 other patients
from the literature were reported to have good control
of their seizures with anti-epileptic medication. Two
children from the literature were described as having
progressively worsening seizures, one presented with sei-
zures shortly after birth and the other was refractory to
medication by the age 10 years [11, 13]. Both patients
had large deletions encompassing DYRK1A in addition
to other genes on chromosome 21.
Results of brain imaging were reported for 42 patients
from the literature. Thirty-two had abnormal findings
(76 %). Enlarged ventricles were described in 22 patients,
general or cortical atrophy in 17 patients, a thin brain-
stem in 13 patients, and a thin corpus callosum in 9 pa-
tients. Other less common findings include pituitary
stalk hypoplasia in 7 cases, a neuronal migration defect
in 1 case, and an enlarged cisterna magna observed in
our case (Fig. 1c). An additional less commonly seen fea-
ture observed in Patient 1 was bilateral optic disc pallor.
Anomalies of the optic disc or optic nerve have been
seen in 6 other individuals with DYRK1A mutations. Vis-
ual abnormalities were seen in 25 of 32 patients, includ-
ing hyperopia, myopia, strabismus, astigmatism,
exotropia, amblyopia, and corneal clouding. There was
also retinal detachment in the oldest individual pub-
lished in the literature, at 59 years.
Dysmorphic features characteristic of a DYRK1A mu-
tation were near universal in 53/54 patients. This in-
cludes deep set eyes with a hooded appearance to the
lateral aspect of the palpebral fissures, a prominent nasal
root, bitemporal narrowing, prominent and dysplastic
ears. Hand and/or foot abnormalities were also seen in
25 patients that included long tapered fingers, small
hands and feet, 5th finger clinodactyly, toe syndactyly,
high arched feet, and proximal placement of the first
toe. Polydactyly was reported in 2 cases. Spinal or
thoracic abnormalities were seen in 11 patients; present-
ing with pectus excavatum, kyphosis, scoliosis, and
abnormal cervical spine. Seventeen patients were re-
ported to have gastrointestinal symptoms, including gas-
troesophageal reflux disease in 12 patients, 3 of whom
required a Nissen fundoplication, recurrent vomiting in
4 patients, pyloric stenosis in 2 patients, and duodenal
atresia in 1 patient.
Our summary of the previously reported cases and our
2 cases highlight relatively rare findings within this
group. Contractures in the digits or lower limbs were
seen in our patient 1 (Fig. 1d) as well as 4 others. An
ataxic gait, seen in patient 2, was also described in 5
other individuals. There have been 10 cases in the litera-
ture that reported recurring or frequent infections. Car-
diac anomalies, including ventricular septal defect
(VSD), patent ductus arteriosis (PDA), and aortic valve
stenosis or insufficiency, were found in 8 cases. There
were 9 reports of genitourinary findings: cryptorchidism
in 3 patients, unilateral renal agenesis, pelvic kidney,
renal cyst, hypospadia, micropenis, and our patient 1
with bilateral hydronephrosis. Though these cardiac and
renal findings are not seen in the majority of patients
with DYRK1A mutations, they should be considered dur-
ing monitoring and long-term care.
A schematic representation of the 35 intragenic and de
novo DYRK1A mutations is shown in Fig. 3. The
DYRK1A protein contains a kinase domain, spanning
from residue 158 – 479 [23]. Other important features
in the N-terminus include a nuclear localization signal
and a DYRK-homology box, a sequence highly con-
served in the DYRK family of unknown function [23,
24]. From residue 588 to 616, there is a targeting signal
that has been shown to cause localization of the protein
to subnuclear compartments associated with splicing
machinery [25]. The majority of mutations occurred
within the kinase domain or in the N-terminal (12 non-
sense, 10 frameshift, and 5 splice site mutations). Of the
6 missense mutations, 5 occurred within the kinase do-
main, potentially leading to diminished protein function.
The only missense mutation falling outside of the func-
tional domain alters the first residue of the speckle-
targeting signal, important for the localization of the
DYRK1A protein. There does not seem to be a clear
genotype-phenotype correlation with the mutations and
the phenotypes reported. There were 4 patients with the
same nonsense mutation, p.Arg205* reported by
Table 2 Summary of the clinical presentation of patients with DYRK1A mutations (Continued)
Genitourinary Bilateral hydronephrosis - 5 / - 3 / - 9 / -
Cardiac PDA - 2 / - 5 / - 8 / -
Recurrent infections + - 7 / - 3 / - 11 / -
SNV single nucleotide variant, FS frameshift, mo Months, yrs Years, IUGR intrauterine growth restriction, SD standard deviation, ADHD attention deficit hyperactivity
disorder, MRI magnetic resonance imaging, GERD gastroesophageal reflux disease, PDA patent ductus arteriosus
a One paper (Ji et al [21]) did not assign the type of abnormalities to each patient, but gave a total prevalence for their cohort. These values have been added to
our total, but were not included in the group subtotals
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different groups and they did not appear to differ from
the majority of cases reported. The recurrence of the
p.Arg205* mutation is likely due to its location in a CpG
dinucleotide, which are mutation hotspots [26].
Conclusion
In summary, children with ID and syndromic features
should be considered for a possible DYRK1A mutation
testing especially if the recognizable facial features are
present. Growth and feeding issues would also support
its potential diagnosis. At the time of diagnosis, abdom-
inal ultrasound, cardiac and ophthalmological assess-
ments would be recommended given the frequency of
anomalies. Genetic counselling would also be recom-
mended in view of the potential for a balanced trans-
location in a parent with a child carrying microdeletions
encompassing DYRK1A [7, 21]. A recurrence due to pos-
sible gonadal mosaicism has yet to be observed. Routine
follow-up with a pediatrician would be highly recom-
mended given feeding issues, growth and developmental
delays.
Consent
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parents of the patients for the publication of this manu-
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ician referral. The study was conducted in accordance
with the Declaration of Helsinki protocols and approved
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by the Editor of the journal.
Abbreviations
DYRK1A: dual-specificity tyrosine phosphorylation-regulated kinase 1A;
ID: intellectual disability; IUGR: intrauterine growth restriction; SD: standard
deviation; MR imaging: MRI, Magnetic resonance imaging;
DNA: deoxyribonucleic acid; RT-PCR: reverse transcriptase polymerase chain
reaction; FISH: fluourescence in situ hybridization; MLPA: multiplex ligation-
dependent probe amplification; NGS: next generation sequencing;
GERD: gastroesophageal reflux disease; VSD: ventricular septal defect;
PDA: patent ductus arteriosus.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SML performed and analyzed the data from literature review and wrote the
manuscript. DP and ES provided the clinical information for the case reports
and made a substantive contribution to the writing and editing of the
manuscript. JDW performed and interpreted the laboratory experiments and
contributed to the writing and editing of the draft manuscript. DAD and HD
conceived the study design, interpreted the exome and clinical data and co-
wrote and edited the manuscript. All authors read and approved the
manuscript.
Acknowledgements
The authors would like to thank the patients and their families, without their
participation this work would not have been possible. The authors would like
to acknowledge Wen Qin and Wendy Mears for their technical assistance. This
work was performed under a grant from the Children’s Hospital of Eastern
Academic Health Science Centres (AHSC) AFP Innovation Fund. DAD is
supported by the CIHR Institute of Genetics Clinical Investigatorship Award. SML
is supported of a CIHR Health Professional Student Research Award. The
authors would also like to thank the Care 4 Rare Consortium and Dr. Kym
Boycott for helpful assistance in all aspects of this work.
A
B
Fig. 3 a The DYRK1A coding sequence with the 5 reported splice site mutations. b The DYRK1A protein with the missense and nonsense
mutations shown above, and the frameshift variants indicated below. The nuclear localization signal shown in red, the DYRK homology (DH) box
shown in purple, the kinase domain shown in blue, and the speckle-targeting signal shown in green. Two mutations were identified in multiple
individuals: p.Arg205* in 4 individuals and p.Glu208Asnfs*3 in 2 individuals
Luco et al. BMC Medical Genetics  (2016) 17:15 Page 7 of 8
Author details
1Department of Genetics, Children’s Hospital of Eastern Ontario, Ottawa, ON
K1H 8L1, Canada. 2Division of Pediatric Neurology, Children’s Hospital of
Eastern Ontario, Ottawa K1H 8L1 ON, Canada. 3Children’s Hospital of Eastern
Ontario Research Institute, Ottawa K1H 8L1 ON, Canada.
Received: 12 August 2015 Accepted: 8 February 2016
References
1. Guimera J, Casas C, Pucharcos C, Solans A, Domenech A, Planas AM, et al. A
human homologue of Drosophila minibrain (MNB) is expressed in the
neuronal regions affected in Down syndrome and maps to the critical
region. Hum Mol Genet. 1996;5(9):1305–10.
2. Hämmerle B, Vera-Samper E, Speicher S, Arencibia R, Martınez S, Tejedor F.
Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in
neural progenitor cells at the transition to neurogenic divisions. Dev Biol.
2002;246(2):259–73.
3. Martinez de Lagran M, Benavides-Piccione R, Ballesteros-Yanez I, Calvo M,
Morales M, Fillat C, et al. Dyrk1A influences neuronal morphogenesis
through regulation of cytoskeletal dynamics in mammalian cortical neurons.
Cereb Cortex. 2012;22(12):2867–77.
4. Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor F, Becker W.
The Down syndrome-related protein kinase DYRK1A phosphorylates
p27Kip1 and Cyclin D1 and induces cell cycle exit and neuronal
differentiation. Cell Cycle. 2014;13(13):2084–100.
5. Chettouh Z, Croquette MF, Delobel B, Gilgenkrants S, Leonard C, Maunoury
C, et al. Molecular mapping of 21 features associated with partial
monosomy 21: involvement of the APP-SOD1 region. Am J Hum Genet.
1995;57(1):62–71.
6. Matsumoto N, Ohashi H, Tsukahara M, Kim KC, Soeda E, Niikawa N. Possible
narrowed assignment of the loci of monosomy 21-associated microcephaly
and intrauterine growth retardation to a 1.2-Mb segment at 21q22.2. Am J
Hum Genet. 1997;60(4):997–9.
7. Bartsch O, Hinkel GK, Petersen MB, König U, Bugge M, Mikkelsen M, et al. A
large family with subtelomeric translocation t (18; 21)(q23; q22. 1) and
molecular breakpoint in the Down syndrome critical region. Hum Genet.
1997;100(5–6):669–75.
8. Møller RS, Kübart S, Hoeltzenbein M, Heye B, Vogel I, Hansen CP, et al.
Truncation of the Down syndrome candidate gene DYRK1A in two
unrelated patients with microcephaly. Am J Hum Genet. 2008;82(5):1165–70.
9. Fujita H, Torii C, Kosaki R, Yamaguchi S, Kudoh J, Hayashi K, et al.
Microdeletion of the Down syndrome critical region at 21q22. Am J Med
Genet A. 2010;152(4):950–3.
10. Oegema R, de Klein A, Verkerk AJ, Schot R, Dumee B, Douben H, et al.
Distinctive Phenotypic Abnormalities Associated with Submicroscopic
21q22 Deletion Including DYRK1A. Mol Syndromol. 2010;1(3):113–20.
11. Yamamoto T, Shimojima K, Nishizawa T, Matsuo M, Ito M, Imai K. Clinical
manifestations of the deletion of Down syndrome critical region including
DYRK1A and KCNJ6. Am J Med Genet A. 2011;155(1):113–9.
12. Van Bon B, Hoischen A, Hehir‐Kwa J, de Brouwer A, Ruivenkamp C, Gijsbers
A, et al. Intragenic deletion in DYRK1A leads to mental retardation and
primary microcephaly. Clin Genet. 2011;79(3):296–9.
13. Valetto A, Orsini A, Bertini V, Toschi B, Bonuccelli A, Simi F, et al. Molecular
cytogenetic characterization of an interstitial deletion of chromosome 21
(21q22. 13q22. 3) in a patient with dysmorphic features, intellectual
disability and severe generalized epilepsy. Eur J Med Genet. 2012;55(5):
362–6.
14. Courcet JB, Faivre L, Malzac P, Masurel-Paulet A, Lopez E, Callier P, et al. The
DYRK1A gene is a cause of syndromic intellectual disability with severe
microcephaly and epilepsy. J Med Genet. 2012;49(12):731–6.
15. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex
targeted sequencing identifies recurrently mutated genes in autism
spectrum disorders. Science. 2012;338(6114):1619–22.
16. Redin C, Gerard B, Lauer J, Herenger Y, Muller J, Quartier A, et al. Efficient
strategy for the molecular diagnosis of intellectual disability using targeted
high-throughput sequencing. J Med Genet. 2014;51(11):724–36.
17. Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Cho MT, Guzman E, et al. The
usefulness of whole-exome sequencing in routine clinical practice. Genet
Med. 2014;16:922–31.
18. Van Bon B, Coe B, Bernier R, Green C, Gerdts J, Witherspoon K, Kleefstra T,
Willemsen M, Kumar R, Bosco P. Disruptive de novo mutations of DYRK1A lead
to a syndromic form of autism and ID. Mol Psychiatry. 2016;21(1):126–32.
19. Ruaud L, Mignot C, Guët A, Ohl C, Nava C, Héron D, et al. DYRK1A
mutations in two unrelated patients. Eur J Med Genet. 2015;58(3):168–74.
20. Bronicki LM, Redin C, Drunat S, Piton A, Lyons M, Passemard S, Baumann C,
Faivre L, Thevenon J, Rivière J. Ten new cases further delineate the
syndromic intellectual disability phenotype caused by mutations in DYRK1A.
Eur J Med Genet. 2015;23(11):1482–7.
21. Ji J, Lee H, Argiropoulos B, Dorrani N, Mann J, Martinez-Agosto JA, Gomez-
Ospina N, Gallant N, Bernstein JA, Hudgins L. DYRK1A haploinsufficiency
causes a new recognizable syndrome with microcephaly, intellectual
disability, speech impairment, and distinct facies. Eur J Med Genet. 2015;
23(11):1473–81.
22. Richer J, Daoud H, Geier P, Jarinova O, Carson N, Feberova J, et al.
Resolution of refractory hypotension and anuria in a premature newborn
with loss‐of‐function of ACE. Am J Med Genet A. 2015;167(7):1654–8.
23. Soundararajan M, Roos AK, Savitsky P, Filippakopoulos P, Kettenbach AN,
Olsen JV, et al. Structures of Down syndrome kinases, DYRKs, reveal
mechanisms of kinase activation and substrate recognition. Structure. 2013;
21(6):986–96.
24. Becker W, Joost H. Structural and functional characteristics of Dyrk, a novel
subfamily of protein kinases with dual specificity. Prog Nucleic Acid Res Mol
Biol. 1998;62:1–17.
25. Alvarez M, Estivill X, de la Luna S. DYRK1A accumulates in splicing speckles
through a novel targeting signal and induces speckle disassembly. J Cell Sci.
2003;116(Pt 15):3099–107.
26. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G,
Gudjonsson SA, Sigurdsson A, Jonasdottir A, Jonasdottir A, Wong WS,
Sigurdsson G, Walters GB, Steinberg S, Helgason H, Thorleifsson G,
Gudbjartsson DF, Helgason A, Magnusson OT, Thorsteinsdottir U, Stefansson
K. Rate of de novo mutations and the importance of father's age to disease
risk. Nature. 2012;488(7412):471–5.
27. Okamoto N, Miya F, Tsunoda T, Kato M, Saitoh S, Yamasaki M, Shimizu A,
Torii C, Kanemura Y, Kosaki K. Targeted next-generation sequencing in the
diagnosis of neurodevelopmental disorders. Clin Genet. 2015;88(3):288–92.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Luco et al. BMC Medical Genetics  (2016) 17:15 Page 8 of 8
